Ratings Canopy Growth Corporation Nasdaq

Equities

CGC

CA1380357048

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
9.38 ^USD	+3.65%		-3.50%	+83.56%

07/05	Investors wary of US cannabis ETFs despite recent rally	RE
07/05	Canopy USA Exercises Options to Acquire Wana, Jetty	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
With an enterprise value anticipated at 4.33 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last few months, analysts have been revising downwards their earnings forecast.
Most analysts recommend that the stock should be sold or reduced.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CANOPY GROWTH CORPORATION	+83.56%	70Cr		-
DONG-E-E-JIAO CO.,LTD.	+43.17%	628.72Cr		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.69%	454.61Cr		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.17%	322.86Cr		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.95%	326.92Cr		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.76%	255.54Cr	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.20%	200.39Cr		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.85%	168.32Cr	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.40%	164.2Cr	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-9.91%	158.67Cr		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes